Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
Go back to Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS| (NASDAQ: AMLX) | Delayed: 34.10 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.10 | 52 Week High | $ | |||
| Open | $34.10 | 52 Week Low | $ | |||
| Day High | $34.10 | P/E | N/A | |||
| Day Low | $34.10 | EPS | $ | |||
| Volume | 3,303 | |||||
